Evaluate the Performance of JOURNEY II CR and JOURNEY II BCS in TKA Populations

NCT ID: NCT04822259

Last Updated: 2022-06-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-28

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

The JOURNEY II BCS Total Knee System (JOURNEY II Bi-cruciate Stabilized Total Knee System) consists of femoral component made from oxidized zirconium (OXINIUM)

The JOURNEY II CR Total Knee System (JOURNEY II Cruciate Retaining Total Knee System ) consists of femoral component made from oxidized zirconium (OXINIUM)

Purpose:

Post-market evidence generation for JOURNEY II BCS and JOURNEY II CR Total Knee System

Objectives:

1. Evaluate the performance of JOURNEY II TKA in Asia-Pacific (APAC) patient populations
2. Establish the equivalent performance between JOURNEY II BCS and JOURNEY II CR to support adoption of JOURNEY II CR

Research participants / locations:

A total of at least 176 knees' information will be collected in up to 10 sites. There will be at least eighty-eight (88) knees for JOURNEY II CR TKA group and at least 88 knees for JOURNEY II BCS TKA group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthroplasty Replacement Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JOURNEY II BCS TKA

Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System

Group Type EXPERIMENTAL

JOURNEY II BCS Total Knee System

Intervention Type DEVICE

Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System

JOURNEY II CR TKA

Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System

Group Type EXPERIMENTAL

JOURNEY II CR Total Knee System

Intervention Type DEVICE

Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JOURNEY II BCS Total Knee System

Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System

Intervention Type DEVICE

JOURNEY II CR Total Knee System

Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with degenerative osteoarthritis.
* Subject is planning to have bilateral Total Knee Arthroplasty (TKA) using JOURNEY II BCS \& CR or have unilateral TKA using JOURNEY II BCS or JOURNEY II CR.\*
* Subject is able and willing to provide voluntary consent to study participation.
* Subject is 18-80 years old (inclusive).

\[\* Bilateral cases can be simultaneous bilateral or staged bilateral (which an interval of 6-8 weeks apart between both knees)\]

Exclusion Criteria

* Subjects with rheumatoid arthritis/inflammatory arthritis, posttraumatic arthritis.
* Previous surgeries including High Tibial Osteotomy (HTO), Unicondylar Knee Arthroplasty (UKA) or Total Knee Arthroplasty (TKA) on the subject knee.
* Subject is pregnant or breast feeding or those at a child-bearing age planning to become pregnant during the follow up.
* Subject does not meet the indication or is contraindicated for JOURNEY II BCS \& JOURNEY II CR's Instructions For Use (IFU).
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Astrid Yung

Role: STUDY_DIRECTOR

Smith & Nephew, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University Third Hospital

Beijing, , China

Site Status

Prince of Wales Hospital

Hong Kong, , China

Site Status

Aster RV Hospital, Bangalore

Bengaluru, Karnataka, India

Site Status

Noble Hospital & Ruby Hall Clinic

Pune, Maharashtra, India

Site Status

Singapore General Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China India Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Journey II CR + BCS.2020.12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

JOURNEY II XR Safety and Effectiveness PMCF
NCT03136887 ACTIVE_NOT_RECRUITING
Journey II BCS EU Observational Trial
NCT02211794 ACTIVE_NOT_RECRUITING